DAMORA THERAPEUTICS, INC. Preferred Stock Dividends, Income Statement Impact
DAMORA THERAPEUTICS, INC. (DMRA) reported Preferred Stock Dividends, Income Statement Impact of $2.71 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2021-11-04
- DAMORA THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2020-09-30 was $2.71M, a 93.65% increase year-over-year.
- DAMORA THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2019-12-31 was $1.40M.
- DAMORA THERAPEUTICS, INC. preferred stock dividends, income statement impact for the quarter ending 2019-09-30 was $1.40M.
- DAMORA THERAPEUTICS, INC. preferred stock dividends, income statement impact for fiscal 2019 was $5.56M.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2020-09-30 | $2.71M 10-Q · filed 2021-11-04 | $7.65M 10-Q · filed 2021-11-04 | ||
| 2019-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $2.80M derived: sum of 2 quarters · filed 2021-03-29 | $5.56M 10-K · filed 2021-03-29 | |
| 2019-09-30 | $1.40M 10-Q · filed 2020-12-11 | $4.16M 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |